Daybue was turned down for Rett syndrome, and Iloperidone for schizophrenia and bipolar I, with safety and benefit-risk concerns cited in both cases.
Antipsychotic medicines are a key part of the pharmacological treatment of schizophrenia. Although they provide therapeutic ...
The U.S. Food and Drug Administration approved Cobenfy on September 26, 2024, making it the first schizophrenia drug with a fundamentally new mechanism of action in more than half a century. Built on ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Cobenfy (xanomeline/trospium chloride; formerly KarXT) was ...
Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the ...
Machine learning can predict many things, but can it predict who will develop schizophrenia years before the average ...
A JAMA Psychiatry analysis estimates schizophrenia costs the U.S. $366.8B in 2024, with nearly 80% of costs driven by ...
The health secretary claimed twice earlier this month that the high-fat, low-carb keto diet can "cure" mental illness.